ESBRIET
As listed in the register: ESBRIET
267 mg · tablet
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Pirfenidone
- Made by
- Hoffmann-La Roche Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Pirfenidone). It describes the substance, not this exact product.
The mechanism of action of pirfenidone in the treatment of IPF has not been established.
In vitro profiling studies in hepatocytes and liver microsomes have shown that pirfenidone is primarily metabolized in the liver by CYP1A2 and multiple other CYPs (CYP2C9, 2C19, 2D6, and 2E1).
Pirfenidone is excreted predominantly as metabolite 5-carboxy-pirfenidone, mainly in the urine (approximately 80% of the dose).
Food decreased the rate and extent of absorption.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-04-22
Safety of the active substance
From the US prescribing label for the same active substance (Pirfenidone). It describes the substance, not this exact product.
The most common (>1%) adverse reactions leading to discontinuation were rash and nausea.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States23 matching products
European UnionNo exact match for this strength and form
Spain16 matching products
- ESBRIET 267 mg · comprimido recubierto con película
- PIRFENIDONA ACCORD 267 mg · comprimido recubierto con película
- PIRFENIDONA AUROVITAS 267 mg · comprimido
- PIRFENIDONA AXUNIO 267 MG · comprimido recubierto con película
- PIRFENIDONA CIPLA 267 mg · comprimido recubierto con película
- PIRFENIDONA DR. REDDYS 267 mg · comprimido recubierto con película
- PIRFENIDONA GLENMARK 267 mg · comprimido recubierto con película
- PIRFENIDONA KERN PHARMA 267 mg · comprimido recubierto con película
Netherlands12 matching products
- Esbriet 267 mg 267 mg · filmomhulde tablet
- Pirfenidon Accord 267 mg 267 mg · filmomhulde tablet
- Pirfenidon Amarox 267 mg filmomhulde tabletten 267 mg · filmomhulde tablet
- Pirfenidon Aurobindo 267 mg 267 mg · tablet
- Pirfenidon Glenmark 267 mg filmomhulde tabletten 267 mg · filmomhulde tablet
- Pirfenidon nio 267 mg filmomhulde tabletten 267 mg · filmomhulde tablet
- Pirfenidon Sandoz 267 mg 267 mg · filmomhulde tablet
- Pirfenidon Teva 267 mg 267 mg · filmomhulde tablet
SwitzerlandNo exact match for this strength and form
Details
| Made by | Hoffmann-La Roche Limited |
|---|---|
| Active substance | Pirfenidone |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 267 mg |
| Form | tablet |
| Classification | L04AX05 · Cancer treatments and immune-system medicines |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02464489 |
| DPD drug code | 95262 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- tablet2 products
- 267 mg
- 801 mg
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.